NecstGen has partnered with Paris-based biotech Astraveus to evaluate the Lakhesys™ Benchtop Cell Factory™, a microfluidic-based platform aiming to simplify and scale CAR-T production. The collaboration will test the system’s potential to reduce cost, footprint, and manual steps in a GMP setting.
The partnership strengthens NecstGen’s role in advancing cell therapy manufacturing and highlights Astraveus’ vision for decentralized, efficient production.
Read more: https://necstgen.com/necstgen-and-astraveus-collaborate-to-evaluate-benchtop-cell-factory-technology-for-scalable-car-t-manufacturing/
Starting Friday, November 14 at 4:00 p.m., two temporary closures (in place for the duration of the Plesmanlaan project, until approximately Q3 2027) will be implemented for...
24 October 2025, Over the past 20 years, Dutch hospitals have filed 559 European patent applications. This emerges from a new study by the European Patent Office and Fraunhofer...
Leiden, 24 October 2025 at 3:03 PMResearchers at LUMC, together with colleagues from the University of Florida, have identified hundreds of proteins in the blood that provide...